Hexamethylamine-CAF (Cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer

C. Sessa, M. D'Incalci, I. Valente

Research output: Contribution to journalArticlepeer-review

Abstract

This study confirms the inefficiency of HMM-CAF as second-line chemotherapy; cisplatin-CAF is also not recommended in patients previously treated with multidrug therapy because the very low response is outweighed by severe toxicity. In general, these conclusions agree with previous failures reported as second-line chemotherapy for ovarian cancer.

Original languageEnglish
Pages (from-to)1233-1234
Number of pages2
JournalCancer Treatment Reports
Volume66
Issue number5
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Hexamethylamine-CAF (Cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer'. Together they form a unique fingerprint.

Cite this